Fresenius SE & Co KGaA (FRA:FRE) received a €61.00 ($70.93) price target from research analysts at Goldman Sachs Group in a research report issued on Friday. The brokerage presently has a “neutral” rating on the stock. Goldman Sachs Group’s target price indicates a potential upside of 41.53% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Commerzbank set a €78.00 ($90.70) price objective on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Friday. Sanford C. Bernstein set a €83.00 ($96.51) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Thursday, August 9th. Barclays set a €80.00 ($93.02) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Friday, August 24th. Cfra set a €70.00 ($81.40) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Wednesday, October 17th. Finally, Warburg Research set a €80.00 ($93.02) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Friday, September 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of €70.39 ($81.85).

Shares of FRE stock opened at €43.10 ($50.12) on Friday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.